Article
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research - 17 Feb 2026
Hollis Robert L, Miller Austin, Lankes Heather A, Wong Kwong-Kwok, Rodgers William, Millan David, Carty Karen, Coleman Robert L, Moore Kathleen N, Alvarez Secord Angeles, O'Malley David M, Chan John K, Hagemann Andrea R, Gaillard Stephanie, Guntupalli Saketh R, Edelson Mitchell I, Rose Peter G, Dorigo Oliver, Banerjee Susana, Ewing Ailith, Churchman Michael, Sood Anil K, Herrington C Simon, Gourley Charlie, Gershenson David M
Abstract excerpt
PURPOSE: Low-grade serous ovarian carcinoma (LGSOC) is a distinct form of ovarian cancer characterized by younger patient age and relative chemoresistance. The GOG281/LOGS trial (NCT02101788) investigated the efficacy of the MEK inhibitor trametinib compared with physician's choice standard-of-care (SOC) in patients with LGSOC with persistent/recurrent disease. The study demonstrated significantly improved...
Topics
Join the communities discussing this publication.